BR9810924A - Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um composto - Google Patents
Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um compostoInfo
- Publication number
- BR9810924A BR9810924A BR9810924-3A BR9810924A BR9810924A BR 9810924 A BR9810924 A BR 9810924A BR 9810924 A BR9810924 A BR 9810924A BR 9810924 A BR9810924 A BR 9810924A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- disorders
- prophylaxis
- pain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000005586 smoking cessation Effects 0.000 title abstract 2
- 206010057852 Nicotine dependence Diseases 0.000 title 1
- 208000025569 Tobacco Use disease Diseases 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000009286 beneficial effect Effects 0.000 title 1
- 230000027288 circadian rhythm Effects 0.000 title 1
- 230000003313 weakening effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- -1 CO ~ 2 ~ R ~ 1 ~ Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702746A SE9702746D0 (sv) | 1997-07-18 | 1997-07-18 | New compounds |
| SE9800977A SE9800977D0 (sv) | 1998-03-24 | 1998-03-24 | New compounds |
| PCT/SE1998/001364 WO1999003859A1 (en) | 1997-07-18 | 1998-07-10 | Novel spiroazabicyclic heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9810924A true BR9810924A (pt) | 2000-08-15 |
Family
ID=26663041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9810924-3A BR9810924A (pt) | 1997-07-18 | 1998-07-10 | Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um composto |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US6110914A (https=) |
| EP (2) | EP1213291B1 (https=) |
| JP (1) | JP2001510194A (https=) |
| KR (1) | KR100560036B1 (https=) |
| CN (1) | CN1117755C (https=) |
| AR (2) | AR013184A1 (https=) |
| AT (2) | ATE283859T1 (https=) |
| AU (1) | AU739022B2 (https=) |
| BR (1) | BR9810924A (https=) |
| CA (1) | CA2296031C (https=) |
| DE (2) | DE69827977T2 (https=) |
| DK (1) | DK0996622T3 (https=) |
| EE (1) | EE04399B1 (https=) |
| ES (2) | ES2185185T3 (https=) |
| HK (1) | HK1046274B (https=) |
| HU (1) | HUP0003844A3 (https=) |
| ID (1) | ID25548A (https=) |
| IL (2) | IL134086A0 (https=) |
| IS (2) | IS2027B (https=) |
| MY (1) | MY116761A (https=) |
| NO (1) | NO325324B1 (https=) |
| NZ (1) | NZ502298A (https=) |
| PL (1) | PL193065B1 (https=) |
| PT (1) | PT996622E (https=) |
| RU (1) | RU2202553C2 (https=) |
| SA (1) | SA98190668B1 (https=) |
| SI (1) | SI0996622T1 (https=) |
| SK (1) | SK283484B6 (https=) |
| TR (1) | TR200000129T2 (https=) |
| TW (1) | TW515799B (https=) |
| WO (1) | WO1999003859A1 (https=) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998054189A1 (en) | 1997-05-30 | 1998-12-03 | Neurosearch A/S | Spiro-quinuclidine derivatives, their preparation and use |
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US6277870B1 (en) * | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2790474B1 (fr) * | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| TWI298068B (en) * | 2000-06-21 | 2008-06-21 | Dainippon Sumitomo Pharma Co | Pharmaceutical composition for schizophrenia |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| BR0210075A (pt) * | 2001-06-01 | 2004-08-17 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa |
| JP2005510482A (ja) * | 2001-10-16 | 2005-04-21 | アストラゼネカ・アクチエボラーグ | 線維筋痛症候群の治療方法 |
| HUP0501017A3 (en) * | 2001-12-14 | 2010-06-28 | Targacept | Methods and compositions for treatment of central nervous system disorders |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| NZ561993A (en) * | 2002-04-18 | 2008-09-26 | Astrazeneca Ab | Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors |
| ES2348282T3 (es) * | 2002-04-18 | 2010-12-02 | Astrazeneca Ab | Compuestos de tienilo. |
| US7417049B2 (en) * | 2002-04-18 | 2008-08-26 | Astrazeneca Ab | Furyl compounds |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| JP4750421B2 (ja) * | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
| EP1598355A4 (en) * | 2003-01-08 | 2010-01-27 | Mitsubishi Tanabe Pharma Corp | THERAPEUTIC ACTIVE FOR THE TREATMENT OF SCHIZOPHRENIA |
| US20050129610A1 (en) * | 2003-06-24 | 2005-06-16 | Johns Hopkins University | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
| AU2004276061A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Ligands |
| WO2005037832A2 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| BRPI0415546A (pt) * | 2003-10-21 | 2006-12-26 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| CN101124012B (zh) | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病的装置 |
| US7732607B2 (en) | 2005-08-22 | 2010-06-08 | Anatoly Mazurov | Heteroaryl-substituted diazatricycloalkanes and methods of use thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| US20080242688A1 (en) * | 2007-03-19 | 2008-10-02 | Astrazeneca Ab | Method 741 |
| CN103977003A (zh) | 2007-04-02 | 2014-08-13 | 帕金森氏病研究院 | 用于降低治疗的副作用的方法和组合物 |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| WO2009046025A1 (en) | 2007-10-01 | 2009-04-09 | Comentis, Inc. | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| KR20100113163A (ko) | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| CN102131791B (zh) | 2008-06-20 | 2014-12-24 | 阿斯利康(瑞典)有限公司 | 二苯并硫杂氮杂*衍生物及其用途 |
| US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| CN102821814B (zh) | 2009-12-23 | 2015-07-15 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的神经刺激设备和系统 |
| US9018227B2 (en) | 2010-03-19 | 2015-04-28 | Indiana State University | Nicotinic acetylcholine receptor agonists |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| RU2455306C1 (ru) * | 2011-05-19 | 2012-07-10 | Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ] |
| BR112013032044A2 (pt) | 2011-06-30 | 2016-12-13 | Toray Industries | antiprurítico |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| US8893339B2 (en) | 2013-03-14 | 2014-11-25 | Select Comfort Corporation | System and method for adjusting settings of a bed with a remote control |
| WO2014202999A1 (en) | 2013-06-21 | 2014-12-24 | Takeda Cambridge Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| JP2017524736A (ja) | 2014-07-11 | 2017-08-31 | アルファーマゲン，エルエルシー | アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物 |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| EP3405255B1 (en) | 2016-01-20 | 2025-12-31 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS |
| EP3405107B1 (en) | 2016-01-20 | 2023-04-12 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| EP3856180A1 (en) | 2018-09-24 | 2021-08-04 | Astrazeneca AB | Azd0328 dosage regime for treating cognitive impairment |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| JP2023512447A (ja) | 2020-01-13 | 2023-03-27 | ザ ファインスタイン インスティチューツ フォー メディカル リサーチ | 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| WO2021236977A1 (en) | 2020-05-21 | 2021-11-25 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| US20250229086A1 (en) | 2022-01-20 | 2025-07-17 | Setpoint Medical Corporation | Treatment of inflammatory disorders |
| CN115340736B (zh) * | 2022-05-20 | 2023-09-29 | 扬州实嘉电缆材料有限公司 | 一种氮磷阻燃剂改性聚氯乙烯防火电缆料 |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681363A (en) * | 1970-08-20 | 1972-08-01 | Univ Temple | Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones |
| RU2029796C1 (ru) * | 1992-06-26 | 1995-02-27 | Научно-производственное предприятие "Новатех" | Способ комбинированной ионно-плазменной обработки изделий |
| ATE192157T1 (de) * | 1994-08-24 | 2000-05-15 | Astra Ab | Therapeutisch verwendbare spiro-azabicyclische verbindungen |
| US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| EP0842178B1 (en) * | 1995-07-28 | 2001-03-28 | Abbott Laboratories | Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
-
1998
- 1998-07-06 AR ARP980103280A patent/AR013184A1/es unknown
- 1998-07-10 PT PT98934078T patent/PT996622E/pt unknown
- 1998-07-10 AT AT02005982T patent/ATE283859T1/de not_active IP Right Cessation
- 1998-07-10 EP EP02005982A patent/EP1213291B1/en not_active Expired - Lifetime
- 1998-07-10 NZ NZ502298A patent/NZ502298A/en unknown
- 1998-07-10 ES ES98934078T patent/ES2185185T3/es not_active Expired - Lifetime
- 1998-07-10 JP JP2000503083A patent/JP2001510194A/ja active Pending
- 1998-07-10 CN CN98809055A patent/CN1117755C/zh not_active Expired - Fee Related
- 1998-07-10 ID IDW20000024A patent/ID25548A/id unknown
- 1998-07-10 AU AU83679/98A patent/AU739022B2/en not_active Ceased
- 1998-07-10 DE DE69827977T patent/DE69827977T2/de not_active Expired - Fee Related
- 1998-07-10 SK SK1835-99A patent/SK283484B6/sk not_active IP Right Cessation
- 1998-07-10 DE DE69808631T patent/DE69808631T2/de not_active Expired - Fee Related
- 1998-07-10 PL PL338259A patent/PL193065B1/pl not_active IP Right Cessation
- 1998-07-10 ES ES02005982T patent/ES2231599T3/es not_active Expired - Lifetime
- 1998-07-10 WO PCT/SE1998/001364 patent/WO1999003859A1/en not_active Ceased
- 1998-07-10 DK DK98934078T patent/DK0996622T3/da active
- 1998-07-10 RU RU2000103958/04A patent/RU2202553C2/ru not_active IP Right Cessation
- 1998-07-10 TR TR2000/00129T patent/TR200000129T2/xx unknown
- 1998-07-10 US US09/171,983 patent/US6110914A/en not_active Expired - Lifetime
- 1998-07-10 EE EEP200000031A patent/EE04399B1/xx not_active IP Right Cessation
- 1998-07-10 AT AT98934078T patent/ATE225792T1/de not_active IP Right Cessation
- 1998-07-10 SI SI9830292T patent/SI0996622T1/xx unknown
- 1998-07-10 BR BR9810924-3A patent/BR9810924A/pt not_active Application Discontinuation
- 1998-07-10 CA CA002296031A patent/CA2296031C/en not_active Expired - Fee Related
- 1998-07-10 HU HU0003844A patent/HUP0003844A3/hu unknown
- 1998-07-10 IL IL13408698A patent/IL134086A0/xx active IP Right Grant
- 1998-07-10 EP EP98934078A patent/EP0996622B1/en not_active Expired - Lifetime
- 1998-07-10 KR KR1020007000526A patent/KR100560036B1/ko not_active Expired - Fee Related
- 1998-07-16 MY MYPI98003255A patent/MY116761A/en unknown
- 1998-07-17 TW TW087111679A patent/TW515799B/zh not_active IP Right Cessation
- 1998-10-26 SA SA98190668A patent/SA98190668B1/ar unknown
-
2000
- 2000-01-13 IS IS5338A patent/IS2027B/is unknown
- 2000-01-17 NO NO20000226A patent/NO325324B1/no not_active IP Right Cessation
- 2000-01-17 IL IL134086A patent/IL134086A/en not_active IP Right Cessation
- 2000-06-16 US US09/594,703 patent/US6369224B1/en not_active Expired - Lifetime
-
2002
- 2002-03-08 US US10/093,939 patent/US6703502B2/en not_active Expired - Fee Related
- 2002-10-16 HK HK02107504.2A patent/HK1046274B/en not_active IP Right Cessation
-
2003
- 2003-03-24 US US10/396,215 patent/US6706878B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/801,085 patent/US7507744B2/en not_active Expired - Fee Related
-
2005
- 2005-03-16 IS IS7747A patent/IS2434B/is unknown
-
2008
- 2008-03-13 US US12/047,425 patent/US20080153864A1/en not_active Abandoned
- 2008-08-22 AR ARP080103670A patent/AR068013A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810924A (pt) | Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um composto | |
| BR0015193A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas | |
| BR9916906A (pt) | Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto | |
| ES2173074T3 (es) | Derivados de xantina, procedimiento para su preparacion y su uso farmaceutico. | |
| NL300124I2 (nl) | Tetracyclische derivaten, werkwijze voor het bereiden daarvan, en hun toepassing. | |
| MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
| BR0015195A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas | |
| UA37178C2 (uk) | Терапевтичні гетероциклічні сполуки, спосіб їх одержання, спосіб профілактики та лікування, лікарський засіб та спосіб його одержання | |
| NO20060972L (no) | Pyridylderivater og deres anvendelse som terapeutiske midler | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| TR200000223T2 (tr) | XA faktörünü engelleyen heterosiklik türevler | |
| NO914960L (no) | Medikamenter for canserterapi med antihistaminegenskaper | |
| NO156690C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater. | |
| NO166126C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater. | |
| ATE186301T1 (de) | An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one | |
| CA2053477A1 (en) | Heterocyclic amine derivatives, their production and use | |
| DK0437128T3 (da) | Anvendelse af et fluorquinolonderivat til fremstilling af et lægemiddel til behandling af pneumocystosis | |
| IT1201934B (it) | Derivati della paromomicina | |
| UA41329C2 (uk) | Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії | |
| NO172541C (no) | Fremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater | |
| NO167147C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive tetrahydroisoksazolo(4,5-c)pyridinderivater. | |
| BR9808546A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto | |
| FR2618435B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| NO20082051L (no) | Arylsubstituert, nitrogeninneholdende, heterofyklisk forbindelse | |
| CY1106913T1 (el) | Προληπτικος παραγων/θεραπευτικος παραγων δια το συνδρομο της φλογωσεως των εντερων που επικρατει της δυσκοιλιοτητος |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE INCIDE NO ARTIGO 8O, 10 ( VIII ), 13, 24 E 25 DA LPI ( 9279/96 ) |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL.8: C07D 491/22, A61K 31/395, A61K 31/435, A61K 31/4353, A61K 31/4355, A61K 31/436, A61K 31/4365, A61K 31/438, A61K 31/439, A61K 31/44, A61K 31/444, A61K 31/4738, A61K 31/4745, A61K 31/496, A61K 31/5377, A61K 31/695, A61P 1/04, A61P 25/04, A61P 25/14, A61P 25/16, A61P 25/18, A61P 25/22, A61P 25/24, A61P 25/28, A61P 25/34, C07D 491/12, C07D 491/20, C07D 495/12, C07F 5/02, C07F 7/18, A61K 31/4427, A61K 31/5375, A61K 31/695, A61P 1/00, A61P 25/00, A61P 43/00, A61P 491/00, C07D 95/00, C07F 5/00, C07F 7/00 Ipc: C07D 491/22 (2008.01), A61K 31/395 (2008.01), A61K |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |